Ionis Pharmaceuticals Inc. (IONS) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted a positive opinion recommending approval of DAWNZERA for the routine prevention of recurrent attacks of hereditary angioedema in adults and adolescents aged 12 years and older.Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic condition characterized by recurrent episodes of severe swelling in various parts of the body, including ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion of DAWNZERAâ.,¢ (donidalorsen) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. The positive opinion is now referred to the European Commission (EC) for an. ...

公司业绩与成就 - 公司过去一年在商业执行和研发管线方面取得重要成就 包括获得三期临床试验数据 [3] - 新药TRYNGOLZA于去年12月获批用于治疗FCS 并且上市后的表现持续超出预期 [4] - 公司已多次上调对TRYNGOLZA的销售预期 目前全年指引为8500万至9500万美元 [4] 商业执行与团队 - 公司对新药TRYNGOLZA的商业化执行感到非常满意 团队表现出色 [4]

Ionis Pharmaceuticals (NasdaqGS:IONS) 2025 Conference November 13, 2025 08:00 AM ET Company ParticipantsKyle Jenne - Chief Global Product Strategy OfficerBeth Hougen - CFOModeratorGood morning. It's my pleasure to be moderating this chat with the Ionis team. With me is Beth Hougen, CFO, and Kyle Jenne, Chief Global Product Strategy Officer. I thought you were Chief Commercial Officer. Is this a slightly different title?Kyle JenneNo, this is the right title. I actually have a Chief Commercial Officer that re ...

融资活动核心条款 - Ionis Pharmaceuticals定价发行7亿美元（或7亿7千万美元，若承销商全额行使超额配售权）的2030年到期、利率0%的可转换优先票据[1] - 票据预计于2025年11月17日完成发行，为无担保债务，不支付常规利息，并于2030年12月1日到期[1][2] - 此次发行净收益预计约为6亿8280万美元（若超额配售权全额行使，则为7亿5120万美元）[3] 资金用途 - 公司计划使用约2亿6760万美元净收益，以现金回购其2026年到期、利率0%的可转换优先票据中的2亿美元本金[4] - 剩余净收益将用于在发行后不时额外回购2026年票据（包括在到期时偿还任何剩余部分）以及一般公司用途[4] 票据转换条款 - 票据初始转换率为每1000美元本金可转换为10.1932股普通股，相当于每股约98.10美元的初始转换价格[5] - 该转换价格较公司2025年11月12日每股72.67美元的收盘价有约35.0%的溢价[5] - 在2030年9月1日或之后至到期日前第二个交易日收盘前，持有人可随时转换全部或部分票据[5] 回购与赎回条款 - 公司在2028年12月6日之前不可赎回该票据，此后若公司普通股股价满足特定条件（如达到有效转换价格的130%并维持一定时间），可选择赎回全部或部分票据[6] - 若公司发生“根本性变化”，持有人可要求公司以现金回购其全部或部分票据，回购价格为票据本金的100%加上应计未付利息[7] 对现有债务的再融资操作 - 在为本批票据定价的同时，公司已与部分2026年票据持有人达成单独协商的交易，以现金回购2亿美元本金的2026年票据[8] - 本次票据发行不以保证回购任何2026年票据为前提[8] 潜在市场影响 - 在回购2026年票据过程中，曾对股权价格风险进行对冲的持有人可能会通过购买公司普通股和/或进行衍生品交易来解除对冲头寸[9] - 此类活动可能显著增加公司普通股的交易量，并可能推高（或减缓下跌）股价，从而导致票据的有效转换价格升高[9]

根据提供的文档内容，该文档不包含任何与公司或行业相关的实质性信息[1]

PresentationOperator Good afternoon, and welcome to Ionis' conference call to discuss olezarsen, Phase III detailed results. As a reminder, this call is being recorded. At this time, I would like to turn the conference over to Wade Walke, Senior Vice President of Investor Relations, to lead off the call. Please begin. ...

领导层交接计划 - 沃伦·巴菲特在致股东信中寻求缓解投资者对其即将退休的担忧 [2] - 巴菲特计划持有公司大量A类股直至股东对新任CEO格雷格·阿贝尔建立信心 [3] - 公司于2021年宣布阿贝尔将接任CEO，并正式确定交接在今年年底进行 [5] 股权变动与慈善捐赠 - 巴菲特将1800股A类股转换为B类股并捐赠给四个家族基金会，捐赠股份价值约13亿美元 [3] - 计划加快对其三个子女基金会的终身捐赠步伐，旨在捐赠其近1500亿美元的全部财富 [5] - 捐赠加速是为了增加其子女在继任受托人接替前完成财富分配的可能性 [5] 公司股价表现与市场观点 - 自CEO交接公告以来，公司股价下跌7%，而同期标普500指数上涨20% [6] - 分析师将股价表现不佳归因于“巴菲特溢价”的消退，即巴菲特个人声誉给股价带来的提振 [6] - 巴菲特强调加速捐赠计划绝不反映其对公司的前景看法发生改变，并表达了对新任CEO的全力支持 [7]

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive an ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Sunday shared results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG), a condition characterized by dangerously high triglyceride (fat) levels.IONS shares are retreating from recent levels. See if it is worth your attention hereThe studies met the primary endpoint, with olezarsen achieving a highly statistically significant placebo-adjusted mean reduction in fasting triglyceride (TG) levels of up to 72% at six m ...